Majority of the pharmaceutical and healthcare industry expects that the costs of decentralised clinical trials (DCTs) will be lower compared with traditional trials.

GlobalData has conducted a survey on different groups of organisations to assess their opinion on how the operational costs will change as they switch to DCTs.

Industry expects DCT costs to be lower compared with traditional trials

Traditional Clinical Trial Cost Compared to Decentralised Clinical Trials 

The survey found that half of clinical/ investigator sites expect the cost to be lower, while 40% of the respondents from the group opined that the costs would remain the same. Only 10% of clinical/ investigator sites said that DCT costs will be higher.

The percentage of other contract service providers which expect the cost of DCTs to be lower than traditional trials stand at 45%. Around 32% of them stated that the costs will remain the same, while the remaining 23% noted that DCTs will lead to an increase in expenses.

Among CROs, 40% believe the cost will increase. The percentage of CRO respondents who expect no change stands at 38%.

Around 38% of Pharma/ Biotech are convinced that costs will drop. However, 32% shared opposing opinion, while the remaining 30% expect no change.

With 40% voting on each side, the Government/Academic Institutes were evenly split between whether DCT costs will be lower or will be the same as traditional trials. The remaining 20% expect it to increase.

The analysis is based on responses received for the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.